Bolenol: Difference between revisions
CSV import |
CSV import |
||
| Line 30: | Line 30: | ||
[[Category:Controlled substances]] | [[Category:Controlled substances]] | ||
{{pharm-stub}} | {{pharm-stub}} | ||
{{No image}} | |||
Revision as of 08:12, 10 February 2025
Bolenol is a synthetic steroid that is part of the anabolic steroid class of drugs. It is also known as 17α-ethyl-19-nortestosterone or as 17α-ethyl-19-norandrost-4-en-17β-ol-3-one. Bolenol is a derivative of nandrolone (19-nortestosterone) which has been ethylated at the 17α position.
History
Bolenol was first described in the scientific literature in 1963. It was developed by the pharmaceutical company Searle Laboratories, which is now part of Pfizer. Bolenol was never marketed, and it is not currently approved for medical use.
Pharmacology
As an anabolic steroid, bolenol has the potential to increase muscle mass and strength. It is thought to work by binding to the androgen receptor, which then influences the expression of certain genes in muscle cells. This can lead to increased protein synthesis and muscle growth.
Bolenol is a prodrug of nandrolone, meaning it is converted into nandrolone in the body. Nandrolone is a potent anabolic steroid that is also used in medicine to treat conditions such as anemia and osteoporosis.
Side Effects
The potential side effects of bolenol are similar to those of other anabolic steroids. These can include acne, hair loss, gynecomastia, and changes in mood or behavior. Long-term use can also lead to serious health problems such as liver damage, heart disease, and infertility.
Legal Status
In many countries, including the United States, bolenol is classified as a controlled substance. This means it is illegal to possess, use, or distribute without a prescription. It is also banned by many sports organizations due to its potential for performance enhancement.
